Cargando…

Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted

PURPOSE: Epoprostenol, used for the treatment of pulmonary arterial hypertension (PAH), has a number of limitations related to its short half-life in aqueous solution. The aim of this study was to evaluate the stability and microbiological properties of a new formulation, namely epoprostenol sodium...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambert, Olivier, Bandilla, Dirk, Iyer, Rupa, Witchey-Lakshmanan, Leonore, Palepu, Nagesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340107/ https://www.ncbi.nlm.nih.gov/pubmed/22563237 http://dx.doi.org/10.2147/DDDT.S29916

Ejemplares similares

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Lambert, Olivier, et al.
Publicado: (2012)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Droplet Size and Distribution of Nebulized 3% Sodium Chloride, Albuterol, and Epoprostenol by Phase Doppler Particle Analyzer
por: McDermott, Kelly, et al.
Publicado: (2021)

Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab)
por: Kim, Jihyun, et al.
Publicado: (2018)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
por: Sonti, Rajiv, et al.
Publicado: (2020)

Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19
por: Poonam, Pai B. H., et al.
Publicado: (2022)

PSAT054 Isolated ACTH Deficiency in a Patient on Epoprostenol
por: Riordan, Marianne, et al.
Publicado: (2022)

Near-Infrared Transflectance Spectroscopy Discriminates Solutions Containing Two Commercial Formulations of Botulinum Toxin Type A Diluted at Recommended Volumes for Clinical Reconstitution
por: Currà, Antonio, et al.
Publicado: (2022)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022)

Physical, chemical, and microbiological stability study of diluted atropine eye drops
por: Saito, Jumpei, et al.
Publicado: (2019)

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
por: Guan, Zheng, et al.
Publicado: (2018)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment
por: Woyke, Simon, et al.
Publicado: (2022)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
por: Yun, Jihoon, et al.
Publicado: (2019)

Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)—An open-label, single-arm study
por: Mihara, Kazuko, et al.
Publicado: (2018)

Stochastic mean-field formulation of the dynamics of diluted neural networks
por: Angulo-Garcia, David, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
por: Chebib, Nader, et al.
Publicado: (2017)

Refractory Cardiogenic Shock from Right Ventricular Infarction Successfully Managed with Inhaled Epoprostenol
por: Held, Natalie, et al.
Publicado: (2017)

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia
por: Li, Jie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ptk0mqrp20dini3of4s5013u32